Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.062 | 0.7 |
mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.018 | 0.7 |
mRNA | Docetaxel | gCSI | pan-cancer | AAC | 0.018 | 0.7 |